Myriad Genetics ( (MYGN) ) has shared an announcement.
On February 24, 2025, Myriad Genetics announced the resignation of CEO Paul J. Diaz, effective April 30, 2025, as he transitions to a role at Cressey & Company. Samraat S. Raha, the current COO, will succeed Diaz as CEO, bringing his expertise in shaping the company’s growth strategy. Concurrently, Mark S. Verratti will be promoted to COO. This leadership transition is part of Myriad’s succession planning and is expected to support the company’s continued growth and innovation. The company also reported strong financial results for 2024, with an 11% increase in revenue and strategic collaborations to enhance its oncology portfolio.
More about Myriad Genetics
Myriad Genetics, Inc. is a leader in genetic testing and precision medicine. The company focuses on providing diagnostic and prognostic tests that help patients and healthcare providers make informed decisions about health management, particularly in the areas of hereditary cancer, tumor profiling, prenatal testing, and pharmacogenomics.
YTD Price Performance: 5.04%
Average Trading Volume: 1,062,998
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.29B
Learn more about MYGN stock on TipRanks’ Stock Analysis page.